老年胶质母细胞瘤的治疗进展

虽然目前在最大限度的安全切除的基础上辅助Stupp方案治疗已经成为大多数指南推荐的成年胶质母细胞瘤（GBM）的标准一线治疗方案，但是该方案中并未包含老年患者（>70岁）。因此，对于占GBM发病人数近50%的老年患者来说，目前仍缺乏统一的标准治疗方案。究其原因可能是老年患者大多体能评分不佳，其他系统合并症较多，以及家庭社会等因素导致老年GBM患者往往不能接受规范化治疗，从而造成总体预后较差。近年来随着对老年GBM患者关注度的逐渐提高，已经有越来越多的相关研究开展。笔者通过对老年GBM的分子病理特征以及最新相关临床研究结果进行综述，为临床选择最佳的个体化治疗方案提供循证医学依据。

Progress on glioblastoma treatment for the elderly

Although maximal safe surgery and adjuvant Stupp protocols are the first line treatment of glioblastoma (GBM) recommended by several guidelines, patients >70 years old are excluded from this protocol. No identical treatment exists for elderly patients who account for nearly 50% of all cases. Elderly patients do not receive standard treatment because of certain reasons, including low physical fitness score, multiple comorbidities, and social and family factors. Hence, the prognosis of the elderly is poor. Many clinical trials have emerged to analyze GBM in elderly patients. This review describes the molecular features and new clinical trials of elderly GBM to provide medical evidence for the individualized treatment of elderly patients.